NEOTHYLLINE Drug Patent Profile
✉ Email this page to a colleague
When do Neothylline patents expire, and when can generic versions of Neothylline launch?
Neothylline is a drug marketed by Teva and is included in two NDAs.
The generic ingredient in NEOTHYLLINE is dyphylline. There are two drug master file entries for this compound. Additional details are available on the dyphylline profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEOTHYLLINE?
- What are the global sales for NEOTHYLLINE?
- What is Average Wholesale Price for NEOTHYLLINE?
Summary for NEOTHYLLINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 104 |
| Patent Applications: | 3,310 |
| DailyMed Link: | NEOTHYLLINE at DailyMed |
US Patents and Regulatory Information for NEOTHYLLINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | NEOTHYLLINE | dyphylline | ELIXIR;ORAL | 007794-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva | NEOTHYLLINE | dyphylline | TABLET;ORAL | 007794-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva | NEOTHYLLINE | dyphylline | INJECTABLE;INJECTION | 009088-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva | NEOTHYLLINE | dyphylline | TABLET;ORAL | 007794-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
